Get to the root of your digestive issues with gut-brain therapy techniques that help you self-manage your gut symptoms in just 6-weeks.
IBS, functional dyspepsia, functional constipation, and functional heartburn are now classified as gut-brain disorders - conditions driven by miscommunication between the gut and brain. The same gut-brain dysfunction also explains why many people with IBD continue to experience pain, constipation, or diarrhea even when their disease is in remission.
When the gut and brain fail to communicate properly, the body can misinterpret normal digestive processes as pain or discomfort. This heightened sensitivity, known as visceral hypersensitivity, can make the gut more reactive and contribute to gastrointestinal symptoms.
Nerva combines evidence-based gut-brain therapy techniques with real human support to help you self-manage symptoms, rebuild confidence, and get back to living fully.
The Nerva program was co-founded by Dr. Simone Peters, who ran a clinical trial with Monash University that found gut-brain therapy therapy worked just as well as the Low FODMAP diet in helping you participants well with and self-manage IBS.
Gut-brain therapy techniques targets the source of the problem: oversensitive nerves in the gut.
Gut-brain therapy techniques teaches you how to address this miscommunication between the gut and brain.
Gut-brain therapy techniques has been shown to help with constipation, diarrhea and mixed IBS.
Studies have shown gut-brain therapy techniques can help you achieve long-lasting IBS management.
Answer questions about you and your gut history to see if Nerva can work for you.
Daily gut-brain sessions, educational content, and goal oriented progress, tailored to your preferences.
Learn skills that can help you teach your brain to ignore false alarms from the gut triggered by food and stress.
Live the life you want, free from the control of digestive diseases.
.png)
Backed by 5+ studies including a randomized controlled trial.
9/10 members see meaningful progress in 4-6 weeks.
Learn skills focused on retraining the gut-brain axis.
Short daily sessions from the comfort of your home.
Kernel32.dll is a . It is not a virus or a third-party component. This DLL handles essential low-level operations including:
Understanding these causes is the first step toward a permanent solution.
The "kernel32.dll" file is a critical component at the core of the Windows operating system. It manages essential functions like memory handling, input/output operations, and interrupt processing. Almost every Windows application relies on this file. The error message indicates that Extreme Injector is trying to access a specific part of this system file within a target process (e.g., your game), but cannot find it. This is typically not a sign that your computer is broken, but rather that there is a between the injector, your system, and the target application.
Scroll down to and click Add or remove exclusions . extreme injector kernel32dll error free
If the kernel32.dll file itself is corrupted or missing due to a previous crash or software conflict, you can use Windows' built-in repair tools to fix it.
In simple terms, your entire Windows operating system relies on kernel32.dll. Without it, Windows cannot boot.
This error, often manifesting as a or a failure to find the entry point, can be frustrating, effectively stopping your work. This article provides a comprehensive guide on understanding, fixing, and running Extreme Injector error-free . What is Extreme Injector and Why Do Errors Happen? Kernel32
. This critical system file is responsible for memory management in Windows. When it glitches, your injector might crash, fail to open, or show "Procedure Entry Point Not Found".
Extreme Injector depends on Microsoft Visual C++ libraries to function properly. Missing or corrupted libraries often lead to kernel32.dll errors.
The typically occurs because the program is unable to access critical system functions required for memory management and process creation. This is often caused by missing system updates, corrupted system files, or security software blocking the injector's deep-level operations. Core Solutions to Fix Kernel32.dll Errors The "kernel32
Did you get this error the app or when clicking Inject ? I can give you more specific steps based on your setup!
Download the latest redistributable packages.
"Hi, it's Alex, one of the founders of Nerva alongside Chris and Dr. Simone Peters.
We designed Nerva to help people with gut-brain disorders get back to a happy, normal life, free of flare-up worries. We're so proud of the fact that we've already helped over 300,000 people live better. Yet, we understand Nerva may not work for some people which is why we have a 100% money back guarantee.
If you finish your 6-week program and think Nerva hasn't helped you manage your symptoms, simply email support for a full refund of the Nerva program."
- Alex Naoumidis, Co-Founder and Co-CEO, Mindset Health
Based on studies that helped 3 in 4 people manage their gut symptoms.
15 minutes a day for 6 weeks. Short and relaxing sessions that fit with your schedule.
Discover helpful and calming flare-up exercises, like our deep breathing techniques.
Listen anytime and anywhere (home, office, couch, you name it).
Learn about gut-brain disorders with a range of easy to understand in-app articles.
Say bye to bots. We have real Nerva team members ready to help!
.svg)
.svg)
1) Anderson, Ellen J. BNutSci, MDiet1,2; Peters, Simone L. BSc (Psychophysiology) (Hons), PhD1; Gibson, Peter R. MBBS(Hons), MD1,2; Halmos, Emma P. BNutDiet, PGradDipBSc, PhD1,2. Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome. The American Journal of Gastroenterology 120(2):p 440-448, February 2025. | DOI: 10.14309/ajg.0000000000002921 2) Peters, S. L., Yao, C. K., Philpott, H., Yelland, G. W., Muir, J. G., & Gibson, P. R. (2016). Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Alimentary pharmacology & therapeutics, 44(5), 447–459. https://doi.org/10.1111/apt.13706
